30% treated |
Secondary attack rate |
θ |
0.966 |
0.966 |
0.961 |
0.955 |
Antiviral treatment efficacy |
εT |
0.025 |
0.025 |
0.025 |
0.024 |
Vaccine efficacy |
εV |
0.001 |
0.002 |
0.006 |
0.012 |
Contact rate |
c |
0.001 |
0.001 |
0.001 |
0.001 |
1/(Duration of infectious period) |
δ |
<0.001 |
0.001 |
<0.001 |
<0.001 |
Proportion of infected individuals hospitalized |
pH |
<0.001 |
0.001 |
<0.001 |
<0.001 |
37% treated |
Secondary attack rate |
θ |
0.946 |
0.945 |
0.941 |
0.935 |
Antiviral treatment efficacy |
εT |
0.043 |
0.043 |
0.043 |
0.042 |
Vaccine efficacy |
εV |
0.001 |
0.002 |
0.006 |
0.012 |
Contact rate |
c |
0.001 |
0.001 |
0.001 |
0.001 |
1/(Duration of infectious period) |
δ |
<0.001 |
0.001 |
<0.001 |
<0.001 |
Proportion of infected individuals hospitalized |
pH |
<0.001 |
0.001 |
<0.001 |
<0.001 |
50% treated |
Secondary attack rate |
θ |
0.881 |
0.881 |
0.877 |
0.872 |
Antiviral treatment efficacy |
εT |
0.101 |
0.100 |
0.100 |
0.099 |
Vaccine efficacy |
εV |
0.001 |
0.002 |
0.006 |
0.011 |
Contact rate |
c |
0.001 |
0.001 |
0.001 |
0.001 |
1/(Duration of infectious period) |
δ |
<0.001 |
0.001 |
<0.001 |
<0.001 |
Proportion of infected individuals hospitalized |
pH |
<0.001 |
0.001 |
<0.001 |
<0.001 |